par Carelli, Claude;Halbreich, Avraham;Achour, Ammar;Zagury, Jean-François;Polliotti, Bruno;Folghera, Susanna;Laaroubi, Khalid;Zagury, Daniel;Bernard, Jacky;Bizzini, Bernard;Lebon, Pierre;Aboud-Pirak, Esther;Burny, Arsène 
;Lowell, George;Picard, Odile
Référence Biomedicine & pharmacotherapy, 46, 4, page (149-153)
Publication Publié, 1992
;Lowell, George;Picard, OdileRéférence Biomedicine & pharmacotherapy, 46, 4, page (149-153)
Publication Publié, 1992
Article révisé par les pairs
| Résumé : | HIV-1 antigens generate in man both a humoral and cellular immune reaction. However, in ARC/AIDS patients, the cellular response is inhibited by HIV-1 which induces an antiproliferative (suppressive) effect on activated T cells. To overcome this inhibition and up-regulate the cellular response, we designed a new vaccine strategy directed both against HIV-1 and immunosuppression and we used an immunizing preparation composed of HIV-1 antigens combined with immunoregulatory peptides prepared in a biologically inactivated but immunogenic form. In mice, this preparation induced anti-HIV-1 antibodies and a cell-mediated cytotoxicity directed against H2 restricted cells carrying HIV-1 antigens. HIV-1 vaccine / immunosuppression / HIV-1 peptides. © 1992. |
